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OBJECTIVE—Melanocortin-4 receptor (MC4R) deﬁciency is
the most frequent genetic cause of obesity. However, there is
uncertainty regarding the degree of penetrance of this condition,
and the putative impact of the environment on the development
of obesity in MC4R mutation carriers is unknown.
RESEARCH DESIGN AND METHODS—We determined the
MC4R sequence in 2,257 obese individuals and 2,677 nonobese
control subjects of European origin and established the likely
functional impact of all variants detected. We then included
relatives of probands carriers and studied 25 pedigrees, including
97 carriers and 94 noncarriers from three generations.
RESULTS—Of the MC4R nonsynonymous mutations found in
obese subjects, 68% resulted in a loss of function in vitro. They
were found in 1.72% of obese versus 0.15% of nonobesed subjects
(P  6.9  10
10). Among the families, abnormal eating behavior
was more frequent in both MC4R-deﬁcient children and adults
than in noncarriers. Although BMI was inversely associated with
educational status in noncarrier adults, no such relationship was
seen in MC4R mutation carriers. We observed a generational
effect, with a penetrance of 40% in MC4R-deﬁcient adults aged
52 years, 60% in 18- to 52-year-old adults, and 79% in children.
The longitudinal study of adult carriers showed an increasing
age-dependent penetrance (37% at 20 years versus 60% at 40
years).
CONCLUSIONS—We have established a robust estimate of
age-related penetrance for MC4R deﬁciency and demonstrated a
generational effect on penetrance, which may relate to the
development of an “obesogenic” environment. It remains to be
seen whether appropriate manipulation of environmental factors
may contribute to preventing the development of obesity even in
those strongly genetically predisposed to it. Diabetes 57:2511–
2518, 2008
T
he leptin-melanocortin axis controls human en-
ergy homeostasis, and the melanocortin-4 recep-
tor (MC4R) is a key player in its central
regulation (1). Loss-of-function mutations in
MC4R cause severe familial forms of obesity (2,3), and
infrequent gain-of-function polymorphisms have been as-
sociated with protection against obesity (4,5). At least 72
nonsynonymous mutations have been discovered so far,
but some have no obvious functional consequences (6,7),
highlighting the importance of functional characterization
of MC4R mutations in the determination of potential
pathogenicity. MC4R is a membrane-bound G-protein–
coupled receptor that activates adenylate cyclase. Loss-of-
function mutations result in a partial or complete loss of
function as measured by cAMP production. The majority
of missense mutations in MC4R result in intracellular
retention of the mutated protein, whereas some primarily
affect ligand binding or ligand/receptor activation (8,9). In
some cases, the alteration of the basal activity of the
receptor (8,10) has been reported.
The prevalence of loss-of-function MC4R mutations
ranges from 0.5 to 5.8% in childhood-onset obesity (11–14).
The contribution of MC4R mutations to late-onset obesity
is still debated (13,15–18). Obesity due to MC4R mutations
has been extensively studied, and although heterozygous
loss-of-function mutations can clearly cause familial obe-
sity, they can be found in individuals who are not obese
(19). There is a need for reliable estimates of penetrance.
Furthermore, no study has thoroughly assessed the effect
of loss-of-function MC4R mutations in elderly subjects.
Previous studies using part of our French cohort evi-
denced the ﬁrst mutation in MC4R and demonstrated that
most of them lead to an intracellular retention of the
receptor (2,13,18).
Although hyperphagia is a key feature of MC4R deﬁ-
ciency, with increased food intake at an ad libitum test
meal reported in severely obese MC4R-deﬁcient children
(10), an apparent amelioration of obesity and food intake
disturbances has been suggested in adulthood in some
studies (6,11). Obesity is a complex trait, and MC4R
mutations offer a unique opportunity to analyze the effects
of both aging and shared environment on the evolution of
body mass in this paradigm. In this extensive study of
2,257 unrelated obese subjects, 2,677 control subjects
of European descent, and 25 multigenerational pedigrees
with several MC4R mutations carriers, we provide a
comprehensive picture of the prevalence of this condition
and of factors that determine the expression of the obesity
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DIABETES, VOL. 57, SEPTEMBER 2008 2511phenotype and support previous observations reported in
a German familial study (20).
RESEARCH DESIGN AND METHODS
The study protocol was approved by all local ethics committees, and informed
consent was obtained from each subject before participation in the study, in
accordance with the Declaration of Helsinki principles. For children younger
than 18 years, oral consent was obtained, and parents provided written
informed consent.
We used the 90th and 97th BMI percentiles as thresholds for childhood
overweight and obesity, respectively, according to the recommendations of
the European Childhood Obesity Group study (21) in a French reference
population (22). The classes of adiposity in adult subjects were deﬁned as lean
(BMI 27 kg/m
2), overweight (BMI 27 and 30 kg/m
2), class I-II obese (BMI
30 and 40 kg/m
2), and class III obese (BMI 40 kg/m
2). Populations are
described in Table 1.
A total of 433 unrelated obese children were recruited through a multime-
dia campaign run by the Centre National de la Recherche Scientiﬁque
(CNRS)-Unite ´ Mixte de Recherche (UMR) 8090, and 93 obese children were
patients of Toulouse Children’s Hospital. French obese adults were recruited
by the CNRS UMR8090 and the Department of Nutrition of Paris Hotel Dieu
Hospital. The cohort includes 160 class I-II and 703 class III unrelated obese
individuals. Some of them have been used in previous studies (18), and the
others were recruited under the same criteria between 1999 and 2003. We also
sequenced 868 Swiss obese subjects, recruited after gastric surgery in Zurich
(15). Their BMI was documented before surgery.
From the D.E.S.I.R. general prospective study, 2,302 control subjects were
selected (23). Selection criteria were BMI 27 kg/m
2 and fasting glucose 5.6
mmol/l at baseline and during the 9-year study follow-up; 375 unrelated white
French adults with BMI 27 kg/m
2 and normal glucose tolerance after an oral
glucose tolerance test recruited at the CNRS UMR8090 were also used as
control subjects. Case and control subjects were not matched for age and sex.
Their mean age at inclusion was 48 years (22.6 kg/m
2; 41% men).
Sequencing. We ampliﬁed the coding sequence of the MC4R gene from a
patient’s genomic DNA in three overlapping fragments. PCR conditions and
primers sequences are available on request. Sequencing was performed using
the automated ABI Prism 3730xl DNA sequencer in combination with the Big
Dye Terminator Cycle Sequencing Ready Reaction kit 3.1 (Applied Biosys-
tems). Sequences were assembled and analyzed with Sequencher software.
Functional characterization of the new mutations. All mutant receptors
were generated from the wild type as previously described (24). Wild-type and
mutant MC4Rs were transiently transfected into HEK293 cells using Lipo-
fectamine 2000 (Stratagene), according to the manufacturer’s instructions.
One hundred nanograms of wild-type or mutant receptors was cotransfected
with 100 ng Bos--galactosidase construct as a control of transfection
efﬁciency.
The response of cells transfected with wild-type and mutant MC4Rs to the
addition of -melanocyte–stimulating hormone (MSH) was measured as
previously described (9). -Galactosidase assay was performed with remain-
ing lysate from cAMP enzyme immunosorbent assay (EIA) as previously
described. The amount of cAMP produced per well was calculated on the
standard curve derived from EIA using GraphPad Prism 4.0 and corrected by
-galactosidase absorbance to correct for transfection efﬁciency. The data
were ﬁtted to the sigmoidal dose-response curve using GraphPad Prism 4.0.
Each experiment was conducted in duplicate at least four times. Mutations
detected in this study were classed as loss of function if they showed
evidence of impaired cAMP generation either in reported studies or in our
investigations.
Familial study. We sequenced MC4R in the voluntary relatives of all
individuals carrying loss-of-function mutations. Pedigrees were available only
for patients recruited by the CNRS UMR8090 unit. This ﬁrst recruitment
already included parents of obese individuals. Proband carriers and children
who were too young to be legally included the previous times were then
contacted until 2006 for the extension of the study to other family members.
Generation determination. To compare the effects of loss-of-function
MC4R mutations between generations, we classiﬁed the relatives of obese
MC4R-deﬁcient probands according to the following thresholds: The end of
childhood was determined as age 18 years, and a generational criterion was
deﬁned by the average age when people became grandparents in our cohort.
Thus, we classiﬁed adult parents as aged 18–52 years and grandparents as
aged 52 years.
Body composition and growth. Probands and relatives have been similarly
phenotyped and genotyped. Weight and height were measured during medical
consultation, and BMI was calculated as weight in kilograms divided by the
square of height in meters. The weights and heights of the children at different
ages from birth to the recruitment were obtained from each child’s health
notebook when available. We then estimated the age of the rebound as
previously described (25). The adiposity rebound corresponds to the second
rise in BMI curve that usually occurs between ages 5 and 7 years. Age of the
obesity onset was deﬁned as the age when BMI ﬁrst exceeded the 97th
percentile for sex and age.
Eating behavior. In obese adults, eating behavior was assessed by the
three-factor eating questionnaire (TFEQ) (26), which evaluates the cognitive
restraint of eating, disinhibition, and hunger. The range of scores for hunger
was 1–14; for disinhibition, 1–18; and for restraint, 1–21. We transformed the
criteria of Stunkard into binary traits using the mean of each criterion for the
thresholds (7, 9, and 10.5, respectively).
Because the TFEQ has not been validated in obese children, we used an
in-house questionnaire administrated by a trained physician (27,28). Three
questions related to eating behavior during or between meals identiﬁed binge
eating, eating large amounts of food during meals, and snacking as binary
phenotypes (yes or no).
Statistical analysis. Comparison of means was done with unpaired Student’s
t test and contingency table 
2 analysis using SPSS 14.0 for Windows. When
the sample size was 30, the statistical signiﬁcance of the difference between
groups was assessed by the Mann-Whitney U test and the Kolmogorov-
Smirnov Z test for nonparametric results. The comparison of prevalence has
been tested with the Fisher’s exact test because of theoretical sample size 5.
Quantitative traits were also analyzed by a linear regression adjusted for age,
sex, and BMI. All reported P values are two sided. P values of 0.05 were
TABLE 1
Phenotypic description of the studied cohorts and results of the mutation screening
n (% male)
Mean age
(SD)
Mean BMI
(SD) Mutations Synonymous Nonsynonymous
Nonsynonymous
loss of function
Control subjects 2,677 (41) 48 (11) 22.6 (2.7) 0.75 (20) 0.22 (6) 0.52 (14) 0.15 (4)
Children 526 (47) 10 (4) — 2.66 (14) 0.38 (1) 2.47 (13) 1.81 (11)
Lille 433 (49) 11 (3) — 2.30 (10) 0.00 (0) 2.31 (10) 2.31 (10)
Toulouse 93 (36) 5 (2) — 4.30 (4) 1.08 (1) 3.23 (3) 1.08 (1)
French adults 863 (30) 44 (14) 41.8 (8.8) 3.24 (28) 0.23 (2) 3.01 (26) 2.32 (20)
Class I-II 160 (36) 48 (15) 36.8 (2.9) 2.50 (4) 0.00 (0) 2.50 (4) 1.25 (2)
Class III 703 (24) 44 (12) 47.0 (7.2) 3.41 (24) 0.28 (2) 3.13 (22) 2.56 (18)
Swiss adults 868 (23) 43 (11) 43.2 (7.3) 1.61 (14) 0.23 (2) 1.38 (12) 0.92 (8)
Class I-II 297 (23) 42 (11) 36.3 (3.2) 0.67 (2) 0.34 (1) 0.34 (1) 0.34 (1)
Class III 571 (23) 43 (10) 46.8 (6.2) 2.10 (12) 0.18 (1) 1.93 (11) 1.23 (7)
All adults 1,731 (28) 46 (13) 42.3 (8.4) 2.43 (42) 0.23 (4) 2.19 (38) 1.61 (28)
Class I-II 457 (33) 47 (14) 34.9 (3.1) 1.31 (6) 0.21 (1) 1.09 (5) 0.65 (3)
Class III 1,274 (24) 45 (12) 47.4 (6.9) 2.82 (36) 0.26 (3) 2.59 (33) 1.96 (25)
All obese 2,257 — — 2.48 (56) 0.22 (5) 2.26 (51) 1.72 (39)
Data are percent of carriers in the cohort (n of carriers) unless otherwise indicated. BMI of the Swiss individuals was documented before
surgery.
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tions with an exchangeable correlation matrix were used with STATA
software to take familial relationships into account when testing the effects of
the mutations.
We used allelic frequencies in case and control subjects from the initial
screening to estimate penetrances, i.e., the probability (PGi), of a given a
genotype (Gi) being affected, where G1 is the wild type, G2 is the heterozy-
gote, and G3 is the mutant homozygote. From Bayes’ theorem, PGi can be
written as P(A Gi)  P(Gi A)  P(A)/[P(Gi A)  P(A)	P(Gi U)  P(U)],
where A stands for affected (obese), U for unaffected, and P(A)i st h e
prevalence of being obese, here identiﬁed as 15% in the European population.
RESULTS
Initial screening of loss-of-function MC4R mutations
Mutation detection. The baseline characteristics of the
1,731 obese adults, 526 obese children, and 2,677 nonobese
control subjects, all of European descent, are reported in
Table 1. We considered as a mutation any rare variant
(frequency 1%) found in the coding sequence. In this
regard, T112M was thus considered as a mutation (12,29),
whereas the more frequent V103I and I251L were excluded
(4,5,30). Among the 2,257 obese subjects, we identiﬁed 36
different mutations (4 synonymous, 31 missense [6 new],
and 1 frameshift) in 56 carriers (2.48%) (Tables 1 and 2;
Fig. 1). Two adults were homozygous carriers for I301T,
and one patient was a compound heterozygous carrier for
Y80X and I301T. In the control group, we identiﬁed 20
carriers of 15 different mutations (0.75%; 5 synonymous
and 10 [5 new] missense). The prevalence rates are given
in Table 1. The enrichment of nonsynonymous mutations
in the obese group compared with the control subjects is
statistically signiﬁcant (Fisher’s exact test, 2.26 vs. 0.52%,
P  9.8  10
8), but there was no difference in the
TABLE 2
Summary of the mutations, name, carriers, and functional characterization
Mutation Obese carriers Nonobese carriers
Functional
characterization Ref.
Known
T11A 1 (45.61) Like wild type (36)
R18C 1 (52.59) Partial (33)
R18H 1 (40.65) Partial (33)
S30F 4 (21.92; 20.10; 20.80; 20.40) Like wild type (36)
Y35X 	 D37V 2 (32.42; 53.67) No activity (29)
InsG48 1 (41.52) No activity (18)
F51L 2 (42.52; 50.68) Like wild type (15)
I69M 1 (45.51) No activity (17)
Y80X 2 (32.51; 49.68 compound htz I301T) No activity (17)
V95I 1 (42.78) No activity (33)
I102T 2 (35.25; 41.09) Partial (17)
T112M 7 (37.17; 20.34; 33.21; 47.58; 31.35; 39.97; 53.93) 1 (24.70) Partial (10)
S127L 2 (36.35; 27.22) Partial (13)
T150I 2 (47.87; 49.94) Partial (10)
A154D 2 (42.62; 39.51) Like wild type (19)
R165W 2 (50.86; 66.95) 1 (24.00) Partial (10)
I170V 3 (33.67; 49.53; 21.90) Partial (10)
M200V 2 (47.62; 45.00) Like wild type (6)
F202L 1 (22.90) Like wild type (34)
G231S 1 (41.62) Partial (17)
A244E 1 (26.28) Like wild type (36)
L250Q 1 (58.82) Partial (13)
G252S 1 (49.78) Partial (36)
V253I 1 (34.47) Like wild type (10)
C271R 1 (28.03) Like wild type (11)
N274S 1 (40.34) Like wild type (36)
S295P 1 (42.19) 2 (25.50; 24.80) Like wild type (17)
P299H 3 (23.30; 26.45; 36.8) No activity (13)
I301T 3 (42.91 hmz; 40.47 hmz; 31.78 htz) Partial (13)
New
H76R 1 (30.84) Like wild type —
S94N 1 (67.86) Partial —
D126Y 1 (42.65) No activity —
D146N 1 (19.20) Like wild type —
Del170V 1 (22.22) Not tested —
F201L 1 (22.30) Partial —
G231V 1 (24.70) Like wild type —
P260Q 2 (23.30; 25.88) Partial —
I289L 1 (20.30) No activity —
R305S 1 (34.31) Partial —
Y332C 1 (20.13) Like wild type —
Y332H 1 (23.00) Like wild type —
Data are n (BMI of the carriers, expressed as weight in kilograms divided by the square of height in meters). hmz, homozygous; htz,
heterzygous.
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groups (0.22 vs. 0.22%, P  1).
Functional characterization. We characterized all
newly identiﬁed missense mutations by testing the ability
of mutated receptors to generate cAMP in response to
increasing concentrations of -MSH. Results are reported
in Fig. 1 and Table 2 (Emax and half-maximal effective
concentration are given in supplementary Table 1, avail-
able in an online appendix at http://dx.doi.org/10.2337/
db08-0153): S94N, F201L, P260Q, and R305S showed a
partial cAMP response to -MSH. D126Y and I289L
showed a complete inability to signal to cAMP. We ob-
served no effect on the cAMP response to increasing
concentrations of -MSH for H76R, D146N, G231V, Y332C,
and Y332H. The other 30 mutations have been character-
ized previously in in vitro assays (references in Table 2).
Of the 34 mutations observed in obese subjects, only 23
(68%) result in a loss of function in vitro. From this
stage, we only analyzed carriers of loss-of-function
MC4R mutations.
Prevalence of loss-of-function MC4R mutations. We
calculated the prevalence of loss-of-function MC4R muta-
tions in our European population. In obese children, the
prevalence was doubled in case of family history of
obesity compared with sporadic obesity (2.31 vs. 1.08%,
respectively). But the difference was not signiﬁcant, which
showed the relative homogeneity of the cohorts and
allowed the calculation of a general prevalence in chil-
dren: altogether, 1.81% of obese children carried loss-of-
function MC4R mutations. In adults, likewise, the
prevalence was higher in probands of obese families
compared with obese subjects in whom there was no
family history of obesity (2.32 vs. 0.92%, P  0.02).
Moreover 1.96% of class III obese subjects harbored loss-
of-function MC4R mutations compared with 0.65% in class
I-II, but the difference was not signiﬁcant (P  0.08). The
mean prevalence of loss-of-function MC4R mutations in
adult obesity was then 1.61%. Altogether, the prevalence in
obese children and adults was 1.72%, whereas 0.15% of
nonobese individuals (mean age 44 years; mean BMI 22.8
compared with 22.6 kg/m
2 in the whole control population;
one man and three women) carried a loss-of-function
mutation (11-fold increase; P  6.9  10
10; Table 1).
Penetrance and mode of inheritance. We evaluated the
penetrance of the loss-of-function MC4R mutations in two
ways. First, we calculated the proportion of carriers of
loss-of-function mutations with obesity in our entire pop-
ulation: 63.5% for heterozygous and 94.6% for homozygous/
compound heterozygous carriers, respectively, according
to the Bayes’ theorem. We also assessed the penetrance of
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FIG. 1. Mutations identiﬁed in MC4R in the screening of 5,620 subjects. A: Localization of the identiﬁed mutation according to MC4R
conformation. The transmembrane domains are indicated as tm1–7, cytoplasmic loops c1–3, and extracellular loops e1–3. Mutations identiﬁed are
listed according to the domain in which they are located. Underlined mutations are new. B: Functional characterization of the new
nonsynonymous mutations: cAMP EIA. The graphs indicate the response of mutant and wild-type MC4R to the addition of a logarithmic increase
of -MSH. Each point represents the mean  SE of at least four independent experiments performed in duplicate.
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erational nonconsanguineous pedigrees where the pro-
band was obese and carried a loss-of-function MC4R
mutation (supplementary Fig. 1). The familial penetrance
was 60% for heterozygous carriers. It was 100% in homozy-
gous and compound heterozygous carriers.
For mutation I301T, we observed a codominant mode of
inheritance: two homozygous unrelated individuals pre-
sented a BMI of 40.5 and 42.9 kg/m
2 compared with a BMI
of 31.78 kg/m
2 for a I301T heterozygous carrier. Moreover,
this heterozygous individual was the father of two
compound heterozygous carriers of I301T plus Y80X
with BMIs of 49.68 and 54.43 kg/m
2, respectively (sup-
plementary Fig. 1). The mother carrying mutation Y80X
had a BMI of 33.05 kg/m
2. The third generation of this
family included two overweight children of 10 and 14
years (BMI 19.0 and 22.3 kg/m
2, respectively; BMI 90th
percentile) carrying either the I301T or the Y80X muta-
tions. The increase in the BMI in homozygous/com-
pound heterozygous compared with heterozygous
carriers was signiﬁcant (P  0.008).
We observed no impact of the severity of the mutations
(Table 2, partial activity vs. no activity) on the severity of
the phenotype of the carriers. Mean BMI for carriers of
mutations leading to a receptor with a partial activity was
33.62 vs. 31.45 kg/m
2 for carriers of one nonfunctional
receptor (P  0.413).
Effects of age on obesity phenotype in MC4R deﬁ-
ciency. We compared obesity-related phenotypes between
carriers and their relatives for children (n  19 vs. 13) and
adults (n  78 vs. 81). Within the 25 pedigrees, as
expected, in each generation, the mean BMI was higher in
mutation carriers compared with relatives with a normal
MC4R genotype (supplementary Table 2). We observed a
gender effect in the whole family sample (	4.3 kg/m
2 in
men and 	8.7 kg/m
2 in women; ref. 20) but the difference
is not signiﬁcant (P  0.19). Children probands were not
bigger than their siblings carrying loss-of-function muta-
tions (26.2 vs. 22.6 kg/m
2, P  0.19), but the difference was
signiﬁcant in adults (45.02 vs. 31.93 kg/m
2, P  0.007).
Onset of obesity and evolution of BMI with age. We
obtained heights and weights of children at different ages
from the individual health record. Although there was a
trend toward earlier development of obesity in MC4R
mutation carriers compared with obese subjects with a
normal MC4R genotype (3.2 vs. 6.0 years), this was not
statistically signiﬁcant (P  0.11). The adiposity rebound
(a strong predictor of the development of childhood
obesity) occurred 3 years earlier in children with MC4R
mutations (2.0 vs. 5.2 years; P  0.006).
In adults, we calculated BMI at 20 years of age from
self-reported heights and weights and compared this with
measured BMI at the age at examination (mean 44 years).
The mean reported BMI of loss-of-function MC4R muta-
tion carriers at 20 years of age (BMI20) was 26.8 kg/m
2.
Probands were all obese at 20 years; among the carrier-
relatives, 22 subjects were normal weight at this age (BMI
90th percentile, 43%), 10 were overweight (BMI 90th
percentile 97th percentile, 20%), and 19 were obese (BMI
97
th percentile, 37%). The BMI20 was slightly but signif-
icantly lower in relatives with a normal MC4R genotype
(24.21 kg/m
2, P  0.04). The BMI of carriers of loss-of-
function MC4R mutations increased signiﬁcantly during
this time frame compared with nonmutation carrier rela-
tives (13.75 vs. 6.18 kg/m
2, P  1.66  10
5). Seven of the
22 (32%)carriers that were nonobese at 20 years showed
late-onset obesity, and 8 of the 10 individuals (80%) who
were overweight became obese.
Effect of generation on BMI and obesity penetrance.
Comparing the carriers of loss-of-function mutations to
their relatives with a normal MC4R genotype in the 25
pedigrees, we observed a signiﬁcant BMI increase of 6.78
kg/m
2 (26.37 vs. 33.15 kg/m
2, P  5.95  10
6).
Adult carriers 52 years were 3 kg/m
2 heavier at 20
years of age than the previous generation at the same age
(data not shown). The disease penetrance was 78% in
children, 60% in adults 52 years old, and 40% in adults
52 years old for obesity (supplementary Table 3). The
decrease in penetrance was signiﬁcant between children
and adults 52 years old (P  0.038). In noncarriers, the
prevalence of obesity was the same in each generation
(23%; supplementary Table 3).
Although carrying a MC4R mutation was consistently
associated with obesity in every generation, the risk of
obesity in carriers was multiplied by 3.4 for children (P 
10
100, Fisher’s exact test), by 2.9 for adults 52 years old
(P  10
84), and by only 1.7 for adults 52 years old (P 
10
11) compared with noncarrier individuals. This de-
crease in risk was signiﬁcant between adults 52 and 52
years old (P  3.0  10
5) and between children and
adults 52 years old (P  9.6  10
4; Fig. 2).
We looked at the genotype distribution of FTO
rs1421085 (31) among the generations and found no dif-
ferences between carriers and noncarriers or among chil-
dren, adults 52 years old, and adults 52 years old (data
not shown).
Eating behavior. An in-house questionnaire distributed
to children assessed three abnormal food intake behav-
iors. There were twice as many children who ate large
amounts of food during meals in the carrier group com-
pared with their noncarrier relatives (61.1 vs. 37.5%; P 
0.25). No obese child was a binge eater, and snacking was
equally frequent in the two groups.
In adults, we used the well-established TFEQ question-
naire (26) and observed a signiﬁcant increase of the
disinhibition score in MC4R mutation carriers compared
with noncarrier relatives (7.2 vs. 5.1, P  0.007; supple-
mentary Table 2). Moreover, the proportion of carriers
harboring a disinhibition rating above the mean score was
37 vs. 12% in noncarrier relatives (P  0.01). The same was
true for the hunger score: 31.0% of carriers above the mean
vs. 10% in noncarrier subjects (P  0.047). Using these
methods, eating behavior was not impaired in adult nono-
bese carriers compared with their noncarrier relatives,
suggesting that the effects of MC4R on eating behavior
may exhibit incomplete penetrance.
We observed a negative relationship between educa-
tional level and BMI in noncarrier adults (P  0.045)
within the families (n  81), as previously reported (32),
but no such correlation was observed for the 78 adult
carriers of loss-of-function MC4R mutations (P  0.42;
data not shown). Apart from BMI and reported eating
behavior, we observed no consistent difference for the
other analyzed clinical traits between carriers and noncar-
riers (supplementary Table 2) in this study.
Exclusion of the probands. To exclude any recruitment
bias, we performed the analyses of the same phenotypes
without the probands. Effects of the mutations on BMI
remained signiﬁcant (	5.17 kg/m
2, P  1.37  10
3);
effects on the other clinical features seemed to remain as
trends, but we were no longer able to observe the gener-
ational effect on penetrance (supplementary Table 4).
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Mutations in MC4R associated with obesity have been
extensively reported, but the true prevalence of this con-
dition has been obscured by several factors. First, the
fundamental difference among loss-of-function, neutral,
and gain-of-function mutations in their major implication
on weight has been ignored by several groups and has led
to conﬂicting and/or inconclusive results regarding the
prevalence of MC4R mutations in different ethnic groups
(14,15). In this study, we highlighted that only 68% of
nonsynonymous mutations in MC4R result in a loss-of-
function in vitro in obese subjects. Thus, the prevalence of
loss-of-function MC4R mutations in our large sample set
of obese subjects of European origin is 1.72%. Although
our mode of recruitment of obese patients may have
tended to overestimate the proportion of severe pheno-
types, the prevalence is consistent with that previously
published in other obese cohorts (14,18,33–35). Our ﬁnd-
ings in the control cohort are consistent with other large,
population-based cohorts (6), such as the KORA-S4 study,
where the prevalence of MC4R mutations was also 0.15%.
It remains also possible that more subtle mutation effects,
such as alteration of the response to other agonists or
antagonists, have not been evidenced by us or by others
(36) and that the prevalence of loss-of-function MC4R is
slightly higher.
By studying 2,257 obese individuals and their family
members (25 multigenerational pedigrees) and 2,677 nono-
bese control subjects, we identiﬁed 108 subjects who
harbored loss-of-function MC4R mutations. This repre-
sents the largest group of MC4R mutation carriers studied
up to now. Our family cosegregation data are consistent
with a codominant mode of inheritance as reported previ-
ously (11). We found that MC4R loss-of-function muta-
tions result in obesity in 63.5% of mutation carriers, and
this value is similar using two different ways of calculation
(case-control study and pedigrees). Thus, the obesity
phenotype associated with loss-of-function MC4R muta-
tions exhibits variable penetrance.
On the contrary, some noncarrier relatives exhibit obe-
sity. This may arise from the so-called phenomenon of
“assortive mating” (i.e., obese people more often get
married with other obese people).
This study establishes the ﬁrst robust estimates of
age-related penetrance for this condition. However, loss-
of-function MC4R mutation adult carriers at 20 years of
age displayed a low penetrance of obesity (37%). One
explanation could be the difference in the environmental
pressure between France, Switzerland, and the U.K. during
the 1980s and an underreported weight at 20 years in
self-administered questionnaires, a recognized phenome-
non especially in overweight/obese people (37). In some
subjects, there was evidence for the development of
obesity caused by MC4R mutations in adult life. Longitu-
dinal familial analysis also provides evidence that the
current obesogenic lifestyle may worsen the effect of
loss-of-function MC4R mutations on childhood and adult
energy, but educational level does not positively impact on
obesity risk among carriers. Nonobese carriers used as
control subjects can develop obesity later in life, even if
our control subjects have been selecting for stable weight
27 kg/m
2 during 9 years; their mean age was 44 years at
inclusion, so they are unlikely to become obese in the near
future.
We also ﬁnd that the penetrance of obesity in those
carrying loss-of-function MC4R mutations seems to have
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FIG. 2. Distribution of individuals according to BMI. We used the ofﬁcial threshold of BMI, percentiles 90 and 97, to discriminate between lean,
overweight, and obese subjects (21) within the 97 carriers and 81 noncarrier relatives from intrafamilial study. The absolute sample sizes of each
subgroup are given above the bars.
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children in multigenerational pedigrees. Of note, the prev-
alence of obesity was similar in each generation in wild-
type carriers of the 25 pedigrees, showing that the
environment alone cannot explain such an effect.
We demonstrated that a common FTO variant does not
inﬂuence severity or penetrance of obesity in our sample
(data not shown). However, sex, age, and generation
impact penetrance and severity of obesity, which conﬁrms
previous observations made by Dempﬂe et al. (20). MC4R
mutation carriers born around the time of the second
World War were much less likely to be obese in childhood,
compared with their offspring born in the 1960s and 1970s
and especially with the 1990s–2000s generation. It is
plausible that the food constraints imposed in France
during and after the second World War (there was ticket-
ing limited access to food until 1947) have delayed obesity,
as suggested by the difference in BMI at 20 years among
mutation carriers of different generations. Our results
agree both with an oligogenic (20) and a codominant (11)
mode of inheritance. We cannot exclude that the increas-
ing distant relationships between the family members
could be a cause of the observed impact of age and
generation on penetrance, but direct effects of relationship
distance and other genetic and environmental factors
remain to be tested to conﬁrm this assumption.
Given the age- and generation-related penetrance of
obesity in carriers of functionally signiﬁcant MC4R muta-
tions, we show that environmental factors contribute to
the development of obesity even in those strongly geneti-
cally predisposed to it. It remains to be seen whether
timely manipulation of environmental factors may be able
to prevent or delay the development of obesity or reduce
its severity in subjects carrying loss-of-function MC4R
mutations.
In conclusion, we have established the ﬁrst robust
estimates of age-related penetrance for this condition and
demonstrated a generational effect on penetrance that may
relate to the development of an obesogenic environment.
In addition, educational level does not impact on obesity
risk among carriers. MC4R deﬁciency may sometimes
present as obesity developing in adult life. Our study also
highlighted the importance of functional analysis in ge-
netic diagnosis of this condition.
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